Aspartate Aminotransferases
Research News and Information

Monday, November 23, 2009

Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico-pathological analysis.

13 Dec 2009 BACKGROUND: Vincristine (VCR) and actinomycin D (ACD) form the backbone of chemotherapeutic regimens of Wilms tumor treatment. Veno-occlusive disease (VOD) is a potentially life-threatening complication of ACD. OBJECTIVES: To investigate the ... Read more...

Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis.

5 Oct 2009 AIM: To investigate the correlation between the antifibrotic effect of baicalin and serum cytokine production in rat hepatic fibrosis. METHODS: Forty male Sprague-Dawley rats were divided randomly into four groups: normal control group, model group, ... Read more...

Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats.

29 Sep 2009 Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are widely used as sensitive markers of possible tissue damage, particularly liver toxicity. Lipid-lowering drugs, such as fibrates, slightly increase serum ... Read more...

Latest indexed articles for 'Aspartate Aminotransferases'

These are the very latest articles for this heading:

• Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: A clinico-pathological analysis. 13 Dec 2009
• Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis. 5 Oct 2009
• Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. 29 Sep 2009
• Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. 29 Sep 2009
• Hemoperfusion with polymyxin B-immobilized fiber column improves liver function after ischemia-reperfusion injury. 26 Sep 2009
• Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. 9 Sep 2009
• [Elevation of liver enzymes in a patient with chronic hepatitis B during alpha-interferon treatment: what is it all about?] 8 Sep 2009
• Helicobacter pylori promotes hepatic fibrosis in the animal model. 5 Sep 2009
• Hepatoprotection of chlorella against carbon tetrachloride-induced oxidative damage in rats. 30 Aug 2009
• Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia. 30 Aug 2009
• An unusual complication: prolonged myopathy due to an alternative medical therapy with heat and massage. 30 Aug 2009
• Hepcidin in acute iron toxicity. 30 Aug 2009
• High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. 30 Aug 2009
• Hepatic damage associated with dengue-2 virus replication in liver cells of BALB/c mice. 29 Aug 2009
• Noninvasive estimation of hepatic steatosis in living liver donors: usefulness of visceral fat area measurement. 25 Aug 2009
• Glutamate metabolic pathways and retinal function. 20 Aug 2009
• Plasma miR-208 as a biomarker of myocardial injury. 18 Aug 2009
• Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. 16 Aug 2009
• Antidiabetic and antilipidemic effect of eremanthin from Costus speciosus (Koen.)Sm., in STZ-induced diabetic rats. 16 Aug 2009
• The German ACROSTUDY: past and present. 12 Aug 2009

See a longer list of these articles.

Technical information about 'Aspartate Aminotransferases'

Definition: Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1.

Chemical name: L-Aspartate:2-oxoglutarate aminotransaminase

Registry Number: EC 2.6.1.1

Descriptor UI: D001219

Alternative terms: Aspartate Aminotransferases; Aminotransferases, Aspartate; Aspartate Apoaminotransferase; Apoaminotransferase, Aspartate; Aspartate Transaminase; Transaminase, Aspartate; Glutamic-Oxaloacetic Transaminase; Glutamic Oxaloacetic Transaminase; Transaminase, Glutamic-Oxaloacetic; L-Aspartate-2-Oxoglutarate Aminotransferase; Aminotransferase, L-Aspartate-2-Oxoglutarate; L Aspartate 2 Oxoglutarate Aminotransferase; Aspartate Aminotransferase; Aminotransferase, Aspartate; Glutamate-Aspartate Transaminase; Glutamate Aspartate Transaminase; Transaminase, Glutamate-Aspartate; SGOT; Serum Glutamic-Oxaloacetic Transaminase; Glutamic-Oxaloacetic Transaminase, Serum; Serum Glutamic Oxaloacetic Transaminase; Transaminase, Serum Glutamic-Oxaloacetic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications;

Tree Number: D08.811.913.477.700.225;

History Note: 2002(1963)

Technical Notes: note specifics